Concomitant lithium and methadone treatment in a bipolar patient: A case report;Tratamiento concomitante de litio y metadona en un paciente bipolar: A propósito de un caso

Adicciones

Volumn 21, Issue 2, 2009, Pages 167-172

  Roncero, Carlos ^a,b   López Ortiz, Cristina ^a   Barral, Carmen ^a   Sáez Francàs, Naia ^a   Rovira, Marc ^a   Casas, Miguel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Bipolar disorder; Dual diagnosis; Lithium; Methadone; Treatment

Indexed keywords

ALBUMIN; FOLIC ACID; GABAPENTIN; GLOBULIN; LACTITOL; LITHIUM CARBONATE; METHADONE; OLANZAPINE; OPIATE; PROLACTIN; SERUM ALBUMIN; SPIRONOLACTONE;

ADULT; ANOREXIA; ARTICLE; BIPOLAR I DISORDER; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CASE REPORT; CHOREA; COGNITIVE DEFECT; COMORBIDITY; DELIRIUM; DIARRHEA; EDEMA; FEMALE; FOLLOW UP; HUMAN; KIDNEY TUBULE DAMAGE; LYMPHOCYTOSIS; MENTAL CONCENTRATION; MIOSIS; MOTOR COORDINATION; NAUSEA; NEUROTOXICITY; OPIATE ADDICTION; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT; TREMOR; VOMITING;

EID: 67650803297     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.244     Document Type: Article

References (43)

1. Callaly T, Trauer T, Munro L, Whelan G. Prevalence of psychiatric disorder in a methadone maintenance population. Aust N Z J Psychiatry 2002; 36: 426-427.
2. Torrens M, Martin-Santos R, Samet S. Importance of clinical diagnoses for comorbidity studies in substance use disorders. Neurotox Res 2006; 10: 253-261.
3. Mateu G, Astals M, Torrens M. Comorbilidad psiquiátrica y trastorno por dependencia de opiáceos: del diagnóstico al tratamiento. Adicciones 2005; 17 Supl 2: 111-121.
4. Brooner RK, King VL, Kidorf M, Schmidt CW, Bigelow GE. Psychiatric and substance use comorbidity among treatment seeking opioid abusers. Arch Gen Psychiatry 1997; 54: 71-80. (Pubitemid 27044701)
5. Krausz M, Verthein U, Degkwitz P. Prevalence of psychiatric disorders in opiate dependent patients in contact with the drug treatment system. Nervenarzt 1998; 69: 557-567. (Pubitemid 28366212)
6. Fernández Miranda JJ, González García-Portilla M, Sáiz Martinez P, Gutiérrez Cienfuegos E, Bobes García J. Influencia de los trastornos psiquiátricos en la efectividad de un programa de mantenimiento prolongado con metadona. Actas Esp Psiquiatr 2001; 29: 228-232. (Pubitemid 33673387)
7. Rodríguez-Llera MC, Domingo-Salvany A, Brugal MT, Silva TC, Sánchez-Niubó A, Torrens M, ITINERE Investigators. Psychiatric comorbidity in young heroin users. Drug Alcohol Depend 2006; 84: 48-55. (Pubitemid 44164315)
8. Weiss RD, Kolodziej M, Griffin ML, Najavits LM, Jacobson LM, Greenfield SF. Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence. J Affect Disord 2004; 79: 279-283. (Pubitemid 38340557)
9. Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry 1995; 56 Supl 3: 19-24.
10. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518
11. Brown ES, Suppes T, Adinoff B, Thomas NR. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord 2001; 65: 105-115.
12. Maremmani I, Perugi G, Pacini M, Akiskal Hs. Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord 2006; 93: 1-12. (Pubitemid 43833247)
13. Freeman MP, Wiegand C, Gelenberg AJ. Litio. En: Schatzberg AF, Nemerof CB, Editores. Tratado de psicofarmacología. 13 ed. Barcelona: Masson; 2006. p. 597-617.
14. Baldessarini RJ, Tarazi FI, Editors. Drugs and the treatment of psychiatric disorders: psychosis and mania. Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 10 Ed. New York: McGraw-Hill, 2001. p. 485-520.
15. Birch NJ, Hullin RP. Lithium and the kidney. Br Med J 1980; 280: 1148-1149
16. Keck PE Jr, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002; 63 Supl 4:3-11. (Pubitemid 34242105)
17. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163-172 (Pubitemid 32762270)
18. Colom J, Duro P, Editores. Tractament de manteniment amb metadona. Manual de pràctica clínica. Barcelona: Generalitat de Catalunya. Departament de Salut; 2005.
19. Vazquez V, Gury C, Laqueille X. Méthadone: de la pharmacocinétique à la pharmacologie clinique. Encéphale 2006; 32 (4 Pt 1): 478-486 (Pubitemid 44320109)
20. Eap CB, Broly F, Mino A, Hämmig R, Déglon JJ, Uehlinger C, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001; 21: 229-234 (Pubitemid 32221062)
21. Moreno Brea MR, Rojas Corrales O, Gibert-Rahola J, Mico JA. Interacciones medicamentosas de metadona con fármacos activos del SNC. Actas Esp Psiquiatr 1999; 27: 103-110
22. Mannisto PT, Saarnivaara L. Effect of lithium on the analgesia caused by morphine and two antidepressants in mice. Pharmacology 1972; 8: 329-335
23. Staunton DA, Deyo SN, Shoemaker WJ, Ettenberg A, Bloom FE. Effects of chronic lithium on enkephalin systems and pain responsiveness. Life Sci 1982; 31: 1837-1840 (Pubitemid 13210365)
24. Flemenbaum A, Cronson AJ, Weddige RL. Lithium in opiate abuse: a theoretical approach. Comprehensive Psychiatry 1979; 20: 91-99 (Pubitemid 9124735)
25. Abrahamson JR. Use of lithium to control drug abuse. Am J Psychiatry 1983; 140: 1256.
26. Liebman JM, Segal DS. Lithium differentially antagonises self-stimulation facilitated by morphine and (+)-amphetamine. Nature 1976; 260: 161-163
27. Tomkiewicz M, Steinberg H. Lithium treatment reduces morphine self-administration in addict rats. Nature 1974; 252: 227-229
28. Dehpour AR Farsam H Azizabadi-Farahani M. Inhibition of the morphine withdrawal syndrome and the development of physical dependence by lithium in mice. Neuropharmacology 1994; 34: 115-121
29. Pani PP, Agus A, Gessa GL. Methadone as a mood stabilizer. Heroin Add & Rel Clin Probl 1999; 1: 43-44.
30. Baño MD, Micó JA, Agujetas M, López ML, Guillén JL. Eficacia del antipsicótico olanzapina en el tratamiento del abuso de cocaína en pacientes en mantenimiento con metadona. Interacción en los niveles plasmáticos. Actas Esp Psiquiatr 2001; 29: 215-220 (Pubitemid 33673385)
31. Gerra G, Di Petta G, D'Amore A, Iannotta P, Bardicchia F, Falorni F, et al. Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol. 2007; 30: 127-135 (Pubitemid 46871862)
32. Martínez-Raga J, Sabater A, Perez-Galvez B, Castellano M, Cervera G. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 599-601. (Pubitemid 38490773)
33. Kharlamb V, Kourlas H. Edema in a patient receiving methadone for chronic low back pain. Am J Health Syst Pharm 2007; 64: 2557-2560 (Pubitemid 350276295)
34. Cardoso F. Chorea: non-genetic causes. Curr Opin Neurol 2004; 17: 433-436
35. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142: 1259-1264 (Pubitemid 16216560)
36. Verebey K, Kogan MJ, Mule SJ. Phencyclidine-induced stereotype in rats: effects of methadone, apomorphine, and naloxone. Psychopharmacology (Berl) 1981; 75: 44-47 (Pubitemid 11020945)
37. Maremmani I, Pacini M, Perugi G, Deltito J, Akiskal H. Cocaine abuse and the bipolar spectrum in 1090 heroin addicts: clinical observations and a proposed pathophysiologic model. J Affect Disord 2008; 106: 55-61.
38. Levinson I, Galynker II, Rosenthal RN. Methadone withdrawal psychosis. J Clin Psychiatry 1995; 56: 73-76
39. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999; 60: 733-740
40. Maremmani I, Zolesi O, Aglietti M, Marini G, Tagliamonte A, Shinderman M, et al. Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis 2000; 19: 29-41. (Pubitemid 30659340)
41. Gaudiano BA, Uebelacker LA, Miller IW. Impact of remitted substance use disorders on the future course of bipolar I disorder: Findings from a clinical trial. Psychiatry Res 2008; 160: 63-71.
42. Grunze H, Amann B, Dittmann S, Walden J. Clinical relevance and treatment possibilities of bipolar rapid cycling. Neuropsychobiology 2002; 45 Supl 1: 20-26 (Pubitemid 34224974)
43. Casas M, Franco MD, Goikoelea JM, Jiménez-Arriero MA, Martínez-Raga J, Roncero C, et al. Trastorno bipolar asociado al uso de sustancias adictivas (patología dual). Revisión sistemática de la evidencia científica y consenso entre profesionales expertos. Actas Esp Psiquiatr 2008; 36: 350-361